Can a special MRI spot seizure hotspots in the brain?
NCT ID NCT02531880
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-stage study is testing whether a contrast agent called mangafodipir can safely highlight areas where the blood-brain barrier is broken in people with drug-resistant epilepsy. Forty adults will undergo MRI scans with mangafodipir and gadolinium to see if these scans can pinpoint the brain region where seizures start. The goal is to improve understanding of epilepsy, not to treat it directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mangafodipir and gadolinium (contrast agents for MRI)
What this could lead to
If successful, this could lead to a new way to identify seizure-causing brain areas using MRI, potentially improving surgical planning for epilepsy.
What could go wrong
This is a very early phase 1 safety and imaging study with only 40 participants. It is not designed to test treatment effects, and the imaging technique may not prove useful in practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••